-
公开(公告)号:US20100129804A1
公开(公告)日:2010-05-27
申请号:US12513637
申请日:2007-11-08
CPC分类号: G01N33/57434 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16 , G01N2333/8135
摘要: Compositions and methods for cancer research, diagnosis, and treatment, including but not limited to, cancer markers are provided. In particular, SPINK1 and other markers for prostate cancer are provided.
摘要翻译: 提供了癌症研究,诊断和治疗的组合物和方法,包括但不限于癌症标志物。 特别地,提供SPINK1和其他前列腺癌标志物。
-
公开(公告)号:US20090104120A1
公开(公告)日:2009-04-23
申请号:US12237512
申请日:2008-09-25
CPC分类号: C12Q1/6886 , C12Q2600/136
摘要: This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to DLX1 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.
摘要翻译: 本发明涉及用于癌症诊断,研究和治疗的组合物和方法,包括但不限于癌症标志物。 特别地,本发明涉及可用作诊断标志物和用于前列腺癌的临床靶标的DLX1癌症标志物。
-
公开(公告)号:US20130225433A1
公开(公告)日:2013-08-29
申请号:US13780585
申请日:2013-02-28
CPC分类号: C12Q1/6886 , C12Q2600/112 , C12Q2600/156 , G01N33/57434 , G01N33/6893
摘要: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to mutations in cancer markers as diagnostic markers and clinical targets for prostate cancer.
摘要翻译: 本发明涉及用于癌症诊断,研究和治疗的组合物和方法,包括但不限于癌症标志物。 特别地,本发明涉及癌症标志物中的突变,作为前列腺癌的诊断标志物和临床靶标。
-
-